Amarantus Bioscience - AMBS.
Company's MANF technology may offer cures for a myriad of diseases. Current focus is on Parkinson's disease.
One of the co-founders of Amgen recently joined the company's board of directors. He stated that the MANF technology holds the potential to generate billions of dollars in revenue.
Read Friday's news about a new licensing agreement.
A "big pharma" development partnership or a buyout could move the share price above $1.00 in 2013.
Multiply your Facebook profits by a factor of 20-25 times.